Search

Additional file 5. Table 4. Pharmacokinetic parameters of theingredients reported for Panax notoginseng. The 8 ingredients and their pharmacokinetic parameters in Panaxnotoginseng were obtained from the online database TCMSP.

Additional file 8. Table 7. Key genes related to coronary heart disease.The 7,100 coronary heart disease-related genes reported were screened outthrough the GeneCards database

Additional file 9. Table 8. Screenedtarget genes of CDDP for CHD treatment. In total, 65 potential target genes of CDDP forCHD treatment were identified.

Additional file 4. Table 3. Pharmacokinetic parameters of theingredients reported in Radix Salviae. The 65 ingredients and their pharmacokinetic parameters in RadixSalviae were obtained from the online database TCMSP.

Additional file 7. Table 6. Genes related to the active ingredients of Panax notoginseng. The screening of ingredient-related genes of Panax notoginsengwas performed using TCMSP and confirmed through the DrugBank database.

Additional file 6. Table 5. Genes related to active ingredients of Radix Salviae. The screening of ingredient-related genes of Radix Salviae wasperformed using TCMSP and confirmed through the DrugBank database

Additional file 3. Table 2. Primers usedfor RT–qPCR in this study. The primers used in this study are listed in thetable.

Additional file 2. Table 1. Composition of CDDP. The main 2 components ofCDDP are listed in the table.

It has been observed that patients on rivaroxaban require more heparin and frequent activated clotting time (ACT) monitoring throughout the catheter ablation of atrial fibrillation, but the strategy of heparin injection varies in different studies. We sought to examine the determinants of heparin dosage in Chinese patients on rivaroxaban.We reviewed consecutive patients who received rivaroxaban before atrial fibrillation ablation and compared them to patients on no anticoagulant. The dosage of heparin required to achieve ACT300 s was evaluated. We then tested determinants of heparin dosage prospectively.There were 124 patients on rivaroxaban (R group) and 42 on no anticoagulant (NA group) in retrospective study. Heparin dosage required to achieve target ACT was 0.89 ± 0.01 mg/kg in R group and 0.60 ± 0.01 mg/kg in NA group, P0.05. The bolus heparin dosage required was 0.77 ± 0.01 mg/kg (96.1 ± 1.1 U/kg) when baseline ACT200 s. In the prospective study, 80/90(88.9%) of patients in R group and 79/90(87.8%) in NA group achieved an ACT300 s after initial bolus injection of heparin. The ACT 60 min after target ACT (ACT60) in R group was higher than that in NA group (287.5 ± 28.3 VS 238.9 ± 29.5, P0.05). Rivaroxaban was the only independent predictor of ACT60. There was no significant difference in ACT or heparin dosage in patients with different duration on or withdrawal of rivaroxaban.In patients undergoing atrial fibrillation ablation on rivaroxaban, the effective duration of heparin is prolonged and the procedural heparin requirement is significantly greater. Heparin dosage can be predicted by baseline ACT, but not influenced by duration on or withdrawal of rivaroxaban.

A model-free compound controller design method is proposed to achieve the wide frequency bandwidth requirement of flight simulators. The method based on quantitative feedback theory, acquires system uncertainty under different working conditions through closed-loop identification with power spectrum estimation. Then in controller designing, it makes a tradeoff between the strict requirements for magnitude-frequency characteristics and those for phase-frequency characteristics of flight simulators, by converting the indices of magnitude-frequency characteristics of flight simulators into quantitative feedback theory-based tracking specification bounds and using feedforward controller to attain the required phase-frequency characteristics. Simulation and experimental results indicate that, when used to design inner frame controller of flight simulator, the proposed method can fulfill the requirements for wide frequency bandwidth indices. Compared with other controller design methods, it has the property of model-free and transparency.